Objective: Sphingosine 1-phosphate is a naturally occurring biologically active lysophospholipid. Recent studies suggested that sphingosine 1-phosphate is released into the blood flow from activated platelets upon stimulation to exert multiple biological phenomenon. The purpose of this study was to assess the effects of sphingosine 1-phosphate on sinus automaticity, ventricular contraction and coronary blood flow. Methods: The canine isolated, blood-perfused sinoatrial node and papillary muscle preparations were used. Results: Sphingosine 1-phosphate increased the sinoatrial rate, while it decreased the coronary blood flow, which was followed by a weak negative inotropic effect. These positive chronotropic and coronary vasoconstrictor effects were not attenuated by the b-and a-adrenoceptor antagonists atenolol and prazosin, respectively. Furthermore, sphingosine 1-phosphate did not affect the adenylate cyclase activity of the membrane preparations made from the canine right atrium and right ventricle, indicating the involvement of a novel signaling pathway in sphingosine 1-phosphate-induced cardiac effects. Conclusions: These results may provide a clue to better understanding the physiological as well as the pathophysiological regulation of sphingosine 1-phosphate in the heart.
Introduction
of Sph-1-P, namely Sph-1-P lyase, but possess strong Sph kinase activity [2, 3] . This enzymatic imbalance causes the Sphingolipid breakdown products play an important role accumulation of Sph-1-P in platelets, which can be reas intercellular as well as intracellular signaling molecules leased extracellularly upon stimulation by agonists includ- [1] . Sphingosine 1-phosphate (Sph-1-P) is the initial ing thrombin, the final product of the clotting cascade product of the catabolism of sphingosine (Sph) by Sph [2, 3] . Recent studies demonstrated that Sph-1-P released kinase, and is then generally cleaved by Sph-1-P lyase to from activated platelets may be involved in a variety of yield ethanolamine phosphate and a fatty aldehyde in most physiological and pathophysiological processes including of the cells [1] . While Sph-1-P had been regarded as an hemostasis, thrombosis and atherosclerosis [1, 5, 6] ; howintermediary metabolite in sphingolipid metabolism in the ever, a precise analysis of acute cardiovascular effects of cells, recent studies have shown that Sph1-P exhibits Sph-1-P is still lacking. several important and specific biological functions besides
The purpose of the present study was to assess the direct the role as an intermediary lipid metabolite [1] [2] [3] [4] .
and acute effects of Sph-1-P on the sinus automaticity, Unlike other cells, platelets lack the degrading enzyme ventricular contraction and coronary blood flow using the canine isolated, blood-perfused sinoatrial node and papillary muscle preparations [7] [8] [9] . After the cardiovascular effects of Sph-1-P were assessed, the preparation was polygraph system (Nihon-Kohden, RM-6000, Tokyo, treated with the b-adrenoceptor antagonist atenolol or Japan). Arterial blood gases were kept within the physioa-adrenoceptor antagonist prazosin to pharmacologically logical range by adjusting the respiratory rate and oxygen assess the possibility that Sph-1-P may release norepinephsupplementation. rine from the viable sympathetic nerve endings in the isolated preparations. Furthermore, the effects of Sph-1-P 2.1.3. Cross-circulation on the adenylate cyclase activity were examined in the The preparations were placed in a double-wall glass cardiac tissue for the first time to explore the signal jacket maintained at 388C by circulating warm water, and transduction systems of Sph-1-P in the heart. perfused with arterial blood from the carotid artery of the donor dog. The perfusion pressure was kept at 120 mm Hg 2. Methods using a peristaltic pump (Cole-Parmer, 7553-20, Chicago, IL) and a Starling's pneumatic resistance placed parallel to Animals were obtained through the Animal Laboratory the perfusion circuit. The coronary blood flow through for Research of Yamanashi Medical University. All experieach nutrient artery was continuously monitored using an ments were performed in accordance with Guidelines for electromagnetic flowmeter (Nihon-Kohden, MVF3200). Animal Experiments of Yamanashi Medical University.
Venous blood from the preparations and excess blood passing through the pneumatic resistance were collected in 2.1. Canine isolated, blood-perfused heart preparations a blood reservoir and returned to the jugular vein of the donor dog. Experiments were carried out using the canine isolated sinoatrial node and papillary muscle preparations cross-2.1.4. Parameters measured circulated with heparinized arterial blood of the blood-
The spontaneously beating rate of the sinoatrial node donor dog [7] [8] [9] . preparation, i.e. the sinoatrial rate, was measured using a cardiotachograph (Nihon-Kohden, AT-601G) triggered by 2.1.1. Isolated preparations the bipolar electrograms obtained from the sinus nodal The preparations were obtained from a beagle dog of region. The papillary muscle preparation was electrically either sex, weighing approximately 10 kg. The dog was driven at a cycle length of 500 ms using a stimulator given heparin calcium (500 U kg , i.v.), and exsanguinKohden, SS-201J). The stimulation pulses were rectanated. The heart was excised and plunged into cold gular in shape, 1-3 V amplitude (about 20% above the Tyrode's solution kept at about 48C. The sinoatrial node threshold voltage) and 5 ms duration. The developed preparation consisted of the entire right atrium. The sinus tension of the papillary muscle preloaded with 2 g weight node artery was cannulated through the right coronary was measured isometrically using a force displacement artery. Bipolar silver-silver chloride electrodes were attransducer (Dia Medical, DRM-T200, Tokyo, Japan) and tached onto the sinus nodal region. The papillary muscle an amplifier (Dia Medical, DRM-T20). The sinoatrial rate preparation consisted of the anterior papillary muscle of and developed tension of the papillary muscle together the right ventricle and the interventricular septum. The with the coronary blood flow through each nutrient artery anterior septal artery, the sole nutrient artery of this were continuously recorded on a rectilinear recorder preparation, was directly cannulated. Bipolar silver-silver (Nihon-Kohden, RJG-4124) at a paper speed of 25 21 chloride pacing electrodes were attached onto the Hismm min . bundle region. Then the papillary muscle preparation was sutured onto an acrylic plate in a size of 30375 mm to the 2.2. Experimental protocol reduce motion artifact derived from the ventricular contraction.
Once the preparations were stabilized, Sph-1-P in doses of 0.01-10 mg (26.4 pmol-26.4 nmol) or its vehicle 2.1.2. Blood-donor dog solution was injected into each nutrient artery using a Adult beagle dogs of either sex, weighing 12-15 kg, small microsyringe (Ito, Tokyo, Japan) in a volume of were used as the blood-donor dog. The dog was anes-10-100 ml over 4 s. Physiological recordings were per-21 thetized with pentobarbital sodium (30 mg kg , i.v.) and formed for 10 min after each dose. Because a relatively mechanically ventilated (Shinano, SN-480-3, Tokyo, small amount of the substance was administered to the Japan). Anesthesia was maintained with supplemental preparations compared to that needed in a whole animal doses of pentobarbital as required. At the start of crossmodel and the preparations were continuously perfused 21 circulation, heparin calcium (500 U kg , i.v.) was given, with Sph-1-P free arterial blood from the donor dog,
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and an additional dose of 200 U kg was intravenously multiple doses of the substance were studied in the same supplemented every hour. The ECG lead II and systemic preparation [7] [8] [9] . The effluent blood through each prepablood pressure were continuously monitored using a ration immediately after the injection of the substance was discarded to eliminate the effects of the substance on the Tokyo, Japan) in triplicate. For the cyclic AMP standard, 5 donor dog. Having assessed the effects of Sph-1-P and ml of a known amount of cyclic AMP was added to the vehicle solution on each parameter, b-adrenoceptor antubes. The cyclic AMP concentration was assayed using tagonist atenolol in a dose of 10 mg or a-adrenoceptor the enzymatic fluorometric method as previously described antagonist prazosin in a dose of 10 mg was administered to [10] [11] [12] . each preparation. Then, the same range of doses of Sph-1-P was administered to compare the effects on the sinoatrial 2.4. Drugs and biochemicals rate and coronary blood flow with those recorded before the treatment of each adrenoceptor antagonist.
The following drugs were purchased: pentobarbital sodium (Tokyo-Kasei, Tokyo, Japan), heparin calcium (Mitsui, Tokyo, Japan), acetylcholine chloride (Daiichi, 2.3. Measurement of adenylate cyclase activity Tokyo, Japan), atropine sulfate (Tanabe, Osaka, Japan) and Sph-1-P (Biomol, Plymouth Meeting, PA). Atenolol, iso-2.3.1. Production of the plasma membrane preparation proterenol, prazosin, phenylephrine, apyrase, phosphoenolAfter the experiment, the heart of the blood-donor dog pyruvate, phosphodiesterase, IBMX, sucrose, fructose, was excised. The sinus nodal area of the right atrium and dithiothreitol and forskolin were obtained from Sigma the papillary muscle of the right ventricle, both weighing Chemical Company (St. Louis, MO, USA). Sph1-P (MW: 50-100 mg, were trimmed, placed in the microcentrifuga-379.5) was dissolved in phosphate-buffered saline with 4 tion tube and homogenized with 1 ml of ice-cold SET solvent to prepare 10 mg ml and 1 mg ml solutions. was filtered through a Nitex filter (Tetko, CA, USA) and
We examined various types of solvent to dissolve Sph-1-P centrifuged at 10 000 g for 5 min at 48C. The pellet was in higher concentration, since a larger volume of injection resuspended in 1 ml of SET buffer and the mixture was to the nutrient coronary artery may affect the cardiovascucentrifuged three more times. The final pellet was relar variables via the dilution of the arterial blood. We found suspended in 500 ml of SET buffer. Protein analysis was the currently used solvent to be the most effective for the performed using a commercially available protein assay 21 present study, which can provide 100 mg ml of Sph-1-P reagent (Pierce, Rockford, IL). The membrane suspension solution. All other enzymes and substrates were obtained was diluted with SET buffer to a concentration of 3-5 mg from Boehringer-Mannheim (Indianapolis, IN, USA).
protein ml , and it was stored at 2808C until its adenylate cyclase activity was measured.
Data analysis and statistics

Enzymatic fluorometric assay of adenylate cyclase
The data are presented as the mean6S.E. The statistical activity comparisons of mean values were carried out using oneThe adenylate cyclase activity of the membrane preparaway repeated-measures ANOVA followed by Contrast, or a tion was measured with an enzymatic fluorometric assay t-test for paired data. A P value less than 0.05 was technique which was essentially the same as that previousconsidered significant. ly described [10] [11] [12] 2310 mol l ) or forskolin (2310 mol l ). Next, the regular automaticity of 8062 beats min (n56). Typical membrane suspension in a volume of 50 ml was added to tracings showing the effects of Sph-1-P on the sinoatrial each tube. The reaction mixture and membrane suspension, rate are shown in Fig. 1(A) (left) , and its dose-response both before and after being mixed, were maintained at 48C curve is shown in Fig. 1 (right) . Administration of a to ensure the same starting time for all assay tubes. The vehicle solution in a volume of 100 ml did not affect the reaction was initiated by placing the tubes in a water bath sinoatrial rate, while Sph-1-P increased it in a dose-depenmaintained at 378C. After 30 min, the reaction was dent manner. Significant differences between Sph-1-P and terminated by heating at 908C for 3 min. The mixture was the vehicle were observed at 3-10 mg for the sinoatrial vortexed three times and centrifuged at 10 000 g for 5 min.
rate. A volume of 5 ml of the supernatant was transferred to a
The basal developed tension of the papillary muscle was 10375 mm disposable assay tube (Iwaki Lab Ware, 6.161.3 g (n56) and the basal coronary blood flow through the anterior septal artery was 9.160.7 ml min administration of the currently used vehicle solution up to (n56). Typical tracings showing the effects of Sph-1-P on 10 times hardly affected the cardiovascular variables the developed tension and the coronary blood flow are measured in this study (n54). shown in Fig. 1(B) (left) , and their dose-response curves are shown in Fig. 1(B) (right) . Administration of the 3.2. Pharmacological analysis of Sph-1-P induced vehicle solution in a volume of 100 ml affected neither the positive chronotropic and coronary vasoconstrictor developed tension nor the coronary blood flow, while effects Sph-1-P decreased both of them in a dose-dependent manner. Significant differences between Sph-1-P and the A typical experiment showing the effects of atenolol in a vehicle were observed at 3-10 mg for the developed dose of 10 mg, which effectively blocked the b-adrenotension, and at 0.3-10 mg for the coronary blood flow.
ceptor for at least 30 min in the current model, on the As another series of experiments, we performed the Sph-1-P induced positive chronotropic effect is shown in cumulative study for the vehicle solution. The repeated Fig. 2(A) (left) , and a summary of the results is shown in Fig. 2(A) (right, n56) . The administration of atenolol agonist phenylephrine but it did not affect the coronary significantly attenuated the effects of b-adrenoceptor agonvasoconstrictor action of Sph-1-P in doses of 0.01-10 mg ist isoproterenol, but it did not affect the positive chrono-(the results for 0.01-3 mg of Sph-1-P were not shown in tropic effects of Sph-1-P in doses of 0.01-10 mg (the the figure) . results for 0.01-3 mg of Sph-1-P were not shown in the figure).
3.3. Effects of Sph-1-P on the adenylate cyclase activity A typical experiment showing the effects of prazosin in a dose of 10 mg, which effectively blocks the a-adreno-
The effects of Sph-1-P and forskolin on the adenylate ceptor at least for 20 min in the current model, on the cyclase activity in membrane preparations obtained from Sph-1-P induced coronary vasoconstrictor effect is shown the right atrium and right ventricle are summarized in 24 21
in Fig. 2 (B) (left), and a summary of the results is shown Table 1 (n55). Forskolin (10 mol l ) significantly in Fig. 2(B) (right, n54) . The administration of prazosin increased the adenylate cyclase activity of the membrane 28 significantly attenuated the effects of the a-adrenoceptor preparations, while Sph-1-P in concentrations of 10 to Table 1 the b-adrenoceptor as well as adenylate cyclase on par- 10 mol l did not affect the adenylate cyclase activity endothelial differentiation genes (edgs) have been found to of these membrane preparations.
be functional Sph-1-P receptors [18] , one(s) transducing Sph-1-P effects in the canine heart need to be clarified. Moreover, it remains to be determined whether other 4. Discussion mechanisms, such as intracellular actions, also contribute to the observed effects of Sph-1-P. Since information regarding the cardiovascular effects of
The observed a-adrenoceptor independent coronary Sph-1-P is still lacking [1] , we assessed the effects of vasoconstrictor action of Sph-1-P also deserves a comSph-1-P on sinoatrial automaticity and ventricular contracment. While there is no report describing the action of tion in addition to the coronary blood flow using the Sph-1-P on the coronary blood flow, it has been shown that 21 well-established canine isolated, blood-perfused sinoatrial Sph-1-P potently increases [Ca ] in human arterial i node and papillary muscle preparations [7] [8] [9] . As clearly smooth muscle cells [4] . Thus, the present results together demonstrated in the present study, Sph-1-P increased the with previous knowledge suggest that Sph-1-P may regsinoatrial rate, while it decreased the coronary blood flow ulate a coronary vascular tone. More importantly, since the and ventricular contraction. This is the first report describsource for Sph-1-P in the coronary vascular system may be ing the positive chronotropic and coronary vasoconstrictor activated platelets [2, 3, 5] , Sph-1-P may play an important effects of Sph1-P, while it has been reported that Sph-1-P role in the pathophysiology of the acute coronary together with sphingosine play mediatory roles in the syndrome [19] . In addition, the current results may also immediate negative inotropic effects of TNFa on cardiac explain several cardiac phenomenon in patients with myocytes [13] . Since the negative inotropic effect was less thrombotic disorders, including blood transfusion toxicity. potent than either of the other effects and appeared after In summary, Sph-1-P induced a sinus tachycardia and coronary vasoconstriction as shown in Fig. 1(B) (left), the coronary vasoconstriction followed by a weak negative currently observed negative inotropic effect of Sph-1-P inotropic effect in the canine isolated heart models under may be at least in part induced by a transient myocardial physiologically maintained electrical and mechanical conischemia besides its direct action. On the other hand, ditions. These observations will provide a clue to better Sph-1-P in broad concentrations did not affect the understanding the physiological as well as the adenylate cyclase activity of the membrane preparations, pathophysiological regulation of Sph-1-P in the heart. suggesting that Sph-1-P does not stimulate the adenylate cyclase activity in particulate. However, this result will not necessarily exclude the hypothesis that Sph-1-P could
